2024
DOI: 10.1136/bmjophth-2023-001565
|View full text |Cite
|
Sign up to set email alerts
|

Genetic analysis of ocular tumour-associated genes using large genomic datasets: insights into selection constraints and variant representation in the population

Alexander Tanner,
Mandeep S Sagoo,
Omar A Mahroo
et al.

Abstract: BackgroundLarge genomic databases enable genetic evaluation in terms of haploinsufficiency and prevalence of missense and synonymous variants. We explored these parameters in ocular tumour-associated genes.MethodsA curated list of ocular tumour-associated genes was assessed using the genomic databases Genome Aggregation Database (gnomAD) and DatabasE of genomiC varIation and Phenotype in Humans using Ensembl Resources (DECIPHER) and compared with breast and lung cancer-associated gene lists. Haploinsufficiency… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…While there are significant improvements in variant calling when SVs are detected against the CHM13-T2T reference (Aganezov et al 2022), the benefits of using the complete genome reference have yet to be determined for somatic variants in a cancer context. Additionally, since CHM13-T2T is still being annotated, the annotated reference genomes GRCh37 and GRCh38 still hold value for ranking and characterizing SVs (Collins et al 2020; Tanner et al 2024). Using both a complete and annotated reference genome would allow researchers to identify novel oncogenic candidate variants across different cancer types.…”
Section: Introductionmentioning
confidence: 99%
“…While there are significant improvements in variant calling when SVs are detected against the CHM13-T2T reference (Aganezov et al 2022), the benefits of using the complete genome reference have yet to be determined for somatic variants in a cancer context. Additionally, since CHM13-T2T is still being annotated, the annotated reference genomes GRCh37 and GRCh38 still hold value for ranking and characterizing SVs (Collins et al 2020; Tanner et al 2024). Using both a complete and annotated reference genome would allow researchers to identify novel oncogenic candidate variants across different cancer types.…”
Section: Introductionmentioning
confidence: 99%